Loss of autonomy related to valproic acid intake [26]

Journal of the American Geriatrics Society

Volumn 54, Issue 12, 2006, Pages 1971-

  Gaubert, Marie Line ^a   Cougnaud, Anne ^a   Ghali, Alaa ^a   Bruhat, Corinne ^a   Diquet, Bertrand ^a   Berrut, Gilles ^a  

^a ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FUROSEMIDE; IRBESARTAN; MEMANTINE; VALPROIC ACID;

AGED; AKINESIA; CASE REPORT; COGNITIVE DEFECT; CONVULSION; DEMENTIA; EPILEPSY; GAIT DISORDER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LETTER; MALE; MUSCLE HYPERTONIA; PARKINSONISM; SMOKING; TREMOR;

AGED, 80 AND OVER; COGNITION DISORDERS; HUMANS; MALE; PARKINSON DISEASE, SECONDARY; VALPROIC ACID;

EID: 33845511828     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2006.00991.x     Document Type: Letter

References (7)

1. Nguyen N, Pradel V, Micallef J et al. [Drug-induced parkinson syndromes.]. Therapie 2004;59:105-112. French.
2. Fariello RG, Varesi M, Smith MC. Valproic acid: mechanism of action. In: Levy RH, Matteson RH, Meldrum BS, eds. Antiepileptic Drugs IV. New York: Raven Press, 1995, pp. 581-588.
3. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245.
4. Masmoudi K, Gras-Champel V, Bonnet I et al. [Dementia and extrapyramidal problems caused by long-term valproic acid.]. Therapie 2000;55:629-634. French.
5. Armon C, Shin C, Miller P et al. Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology 1996;47:626-635.
6. Masmoudi K, Gras-Champel V,Masson H et al. Parkinsonism and/or cognitive impairment with valproic acid therapy: A report of ten cases. Pharmacopsychiatry 2006;39:9-12.
7. Leppik IE. Choosing an antiepileptic. Selecting drugs for older patients with epilepsy. Geriatrics 2005;60:42-47.